Last Stop Before Exit – Hepatitis C Assembly and Release as Antiviral Drug Targets
AbstractChronic Hepatitis C infection is a global health problem. While primary infection is often inapparent, it becomes chronic in most cases. Chronic infection with Hepatitis C virus (HCV) frequently leads to liver cirrhosis or liver cancer. Consequently, HCV infection is one of the leading causes for liver transplantation in industrialized countries. Current treatment is not HCV specific and is only effective in about half of the infected patients. This situation underlines the need for new antivirals against HCV. To develop new and more efficient drugs, it is essential to specifically target the different steps of the viral life cycle. Of those steps, the targeting of HCV assembly has the potential to abolish virus production. This review summarizes the advances in our understanding of HCV particle assembly and the identification of new antiviral targets of potential interest in this late step of the HCV life cycle. View Full-Text
Share & Cite This Article
Tews, B.A.; Popescu, C.-I.; Dubuisson, J. Last Stop Before Exit – Hepatitis C Assembly and Release as Antiviral Drug Targets. Viruses 2010, 2, 1782-1803.
Tews BA, Popescu C-I, Dubuisson J. Last Stop Before Exit – Hepatitis C Assembly and Release as Antiviral Drug Targets. Viruses. 2010; 2(8):1782-1803.Chicago/Turabian Style
Tews, Birke Andrea; Popescu, Costin-Ioan; Dubuisson, Jean. 2010. "Last Stop Before Exit – Hepatitis C Assembly and Release as Antiviral Drug Targets." Viruses 2, no. 8: 1782-1803.